Dual antiplatelet therapy in patients with Stable Ischemic heart disease

Joseph Walker Keach, Robert W. Yeh, Thomas M. Maddox

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Dual antiplatelet therapy (DAPT) is the use of a P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor) in combination with aspirin. Recommendations for its use are primarily in patients who have experienced acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) in the preceding 12 months. There is a growing body of evidence, however, investigating the use of long-duration DAPT in patients with stable ischemic heart disease (SIHD). SIHD is defined as clinical evidence of ischemic heart disease, without an ACS event in the preceding 12 months, and includes patients with stable angina, elective PCI, and remote history of ACS. The use of DAPT in the SIHD population and the recent advancements in our under- standing of its use are the focus of this review.

Original languageEnglish
Article number5
JournalCurrent Atherosclerosis Reports
Issue number1
StatePublished - Jan 2016


  • Aspirin
  • Clopidogrel
  • Coronary artery disease
  • Dual antiplatelet therapy
  • Myocardial infarction
  • Prasugrel
  • Stable ischemic heart disease
  • Ticagrelor


Dive into the research topics of 'Dual antiplatelet therapy in patients with Stable Ischemic heart disease'. Together they form a unique fingerprint.

Cite this